Citation Impact
Citing Papers
Matrix Protein CCN1 Is Critical for Prostate Carcinoma Cell Proliferation and TRAIL-Induced Apoptosis
2009 Standout
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
2004
Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias
2003
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds
2007 Standout
Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen.
1998
Testicular Germ-Cell Cancer
1997 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Prostate cancer
2008
Aromatase Inhibitors in Breast Cancer
2003
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
An open randomised trial of second-line endocrine therapy in advanced breast cancer
2003
Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer1
2007
A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
2008
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
1999 Standout
Inhibition of Metastases by Anticoagulants
1999
Management of gynaecomastia in patients with prostate cancer: a systematic review
2005
Bicalutamide (Casodex®) in the treatment of prostate cancer
2004
Clinical trials with anticoagulant and antiplatelet therapies
1992
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
Use of bisphosphonates in cancer patients
1996
Epidemiology of Prostate Cancer
2019 Standout
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
2008
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
1993
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
2003 Standout
The development of androgen-independent prostate cancer
2001 Standout
Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853
1998
Molecular mechanisms of cisplatin resistance
2011 Standout
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial
2005
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
2005
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3
2003
The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer
1995
Coumarins: Old Compounds with Novel Promising Therapeutic Perspectives
2010 Standout
Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
2004 Standout
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma
2003
Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
1993
EAU Guidelines on Prostate Cancer
2007 Standout
Male breast cancer
2006 Standout
The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy
2003
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
1998
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial
1995
Primary Retroperitoneal Lymph Node Dissection in Clinical Stage A Non‐seminomatous Germ Cell Testis Cancer Review of the Indiana University Experience 1965–1989
1993
Cancer treatment and survivorship statistics, 2012
2012 Standout
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
2011 Standout
Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands
2005
Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
2007
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Drug discovery from medicinal plants
2005 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia
2004
Biaryl Phosphane Ligands in Palladium‐Catalyzed Amination
2008 Standout
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
2010
Hypoxia-inducible factor 1 and breast cancer metastasis
2015 StandoutNobel
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
2006 Standout
HOW IS ANDROGEN-DEPENDENT METASTATIC PROSTATE CANCER BEST TREATED?
1996
Endocrine treatment in prostate cancer
2000
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Bisphosphonate treatment of osteoporosis
2003
Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
2002
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry
2014 Standout
NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin–Aromatase Interactions
2014
Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients
1994 Standout
The Complex Role of Estrogens in Inflammation
2007 Standout
Intracranial germ-cell tumors: natural history and pathogenesis
1985 Standout
Antiandrogens as Monotherapy for Prostate Cancer
1998
Nontoxic Doses of Suramin Enhance Activity of Doxorubicin in Prostate Tumors
2001
Germ-Cell Testicular Cancer in Adults
1979
Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
2012
Retroperitoneal Lymphadenectomy for Clinical Stage a Testis Cancer (1965 to 1989): Modifications of Technique and Impact on Ejaculation
1993
Aromatase inhibitors as potential cancer chemopreventives.
1998
Osteoporosis during androgen deprivation therapy for prostate cancer
2002
Guidelines on the Diagnosis and Management of Pericardial Diseases Executive SummaryThe Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology
2004 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
2005 Standout
Aromatase Inhibitors in the Treatment of Breast Cancer
2005
LIMITATIONS IN THE USE OF SERUM PROSTATE SPECIFIC ANTIGEN LEVELS TO MONITOR PATIENTS AFTER TREATMENT FOR PROSTATE CANCER
2005
STEROID HORMONE WITHDRAWAL SYNDROMES
1997
Estrogen Suppression in Males: Metabolic Effects1
2000
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
2005
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
2009
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
2001 Standout
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
2000 Standout
Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer
2000
Evolution of the Management of Stage I Nonseminomatous Germ-cell Tumors of the Testis
1991
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER
2004
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
2009 Standout
Breast Cancer and the Role of Cytokines in Regulating Estrogen Synthesis: An Emerging Hypothesis
1997
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
2006 Standout
Skeletal complications of malignancy
1997 Standout
GYNECOMASTIA AND BREAST PAIN INDUCED BY ADJUVANT THERAPY WITH BICALUTAMIDE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PROSTATE CANCER: THE ROLE OF TAMOXIFEN AND RADIOTHERAPY
2005
The Anthracycline Antineoplastic Drugs
1981 Standout
Steroidal and Nonsteroidal Sulfamates as Potent Inhibitors of Steroid Sulfatase
1998
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy
2004
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Bicalutamide Monotherapy Versus Leuprolide Monotherapy for Prostate Cancer: Effects on Bone Mineral Density and Body Composition
2004
Non‐competitive steroid inhibition of oestrogen receptor functions
2002
Germ-Cell Testicular Cancer in Adults
1979
Evaluation of Tamoxifen and Anastrozole in the Prevention of Gynecomastia and Breast Pain Induced by Bicalutamide Monotherapy of Prostate Cancer
2005
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
2006
Cancer de la prostate
2007
Testicular Germ-Cell Neoplasms: Recent Advances in Diagnosis and Therapy
1979
Works of C. Tyrrell being referenced
Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial
1994
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
2006
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
1996
Casodex<sup>TM</sup> 10–200 mg Daily, Used as Monotherapy for the Treatment of Patients with Advanced Prostate Cancer
1998
Tolerability and Quality of LifeAspects with the Anti-AndrogenCasodex (IC1176,334) asMonotherapy for Prostate Cancer
1994
Multicenter randomized trial comparing zoladex with zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update
1993
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years
1998
Adjuvant and Neoadjuvant Hormonal Therapy for Prostate Cancer
1999
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program
2004
Bicalutamide (‘Casodex’) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme
2005
Megestrol Acetate in Relapsed Carcinoma of Prostate
1990
Response of Carcinoma of the Prostate to Withdrawal of Flutamide
1993
A pilot study of stanozolol for advanced breast carcinoma
1991
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
2001
The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study
2003
Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer
1995
Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
1998
A Multicenter Randomized Trial Comparing the Luteinizing Hormone-Releasing Hormone Analogue Goserelin Acetate Alone and with Flutamide in the Treatment of Advanced Prostate Cancer
1991
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
2006
The role of ultrasound in the assessment and treatment of abdominal metastases from testicular tumours
1977
Efficacy and Tolerability of Radiotherapy as Treatment for Bicalutamide-induced Gynaecomastia and Breast Pain in Prostate Cancer
2004
Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program
2002
Intravenous pamidronate: infusion rate and safety.
1994
Prophylactic breast irradiation significantly reduces the incidence of bicalutamide (‘Casodex’)-induced gynecomastia
2002
Two case reports of tamoxifen as a cause of impotence in male subjects with carcinoma of the breast
1993
The Response of Lymph Node Metastases of Testicular Teratoma to Radiation Therapy
1976
Open-label phase II study of ZD0473 in patients with metastatic hormone refractory prostate cancer
2001
Pericardiocentesis and systemic cytotoxic chemotherapy in the management of cardiac tamponade secondary to disseminated breast carcinoma.
1988
BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP
2000